Prostatilen

Hormonal / Prostate

Also known as: Samprost, Vitaprost, Простатилен, Prostate Extract, Bovine Prostate Peptides

Bioregulators (Khavinson Peptides)Research phase: Post-marketing (Russia), extensive clinical useRegulatory: Approved in Russia as a pharmaceutical for chronic prostatitis and BPH. Multiple formulations: IM injection, rectal suppositories, oral tablets. Not FDA-approved. Not EMA-approved. One of the best-selling Khavinson products in Russia.

Mechanism

Prostatilen is a pharmaceutical-grade peptide extract from bovine prostate tissue, approved in Russia for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). It reduces prostate inflammation, swelling, and pain while improving urinary flow and sexual function. Available as both injectable and suppository formulations, it is one of the most commercially successful Khavinson-derived products. Russian clinical data shows significant improvement in prostate symptoms and quality of life scores.

Technical detail

Prostatilen is a lyophilized polypeptide complex (<10 kDa) extracted from bovine prostate glands. Contains tissue-specific peptides with affinity for prostatic epithelial and stromal cells. Mechanisms: (1) Anti-inflammatory — reduces leukocyte infiltration, suppresses IL-8, TNF-α, and COX-2 expression in prostatic tissue; (2) Anti-edematous — normalizes vascular permeability in prostate microvasculature, reducing glandular swelling; (3) Antimicrobial — enhances local immune defense by stimulating secretory IgA and lysozyme production in prostatic secretions; (4) Antithrombotic — prevents microthrombosis in prostatic vasculature, improving glandular blood flow; (5) Smooth muscle modulation — normalizes detrusor/sphincter coordination for improved urinary flow. Russian clinical data: significant improvement in NIH-CPSI scores (pain, urinary, quality of life domains) in chronic prostatitis. Marketed as Prostatilen (IM injection), Vitaprost (suppository/tablet), and Samprost. Extensive post-marketing data in Russia.

Evidence

[The validation of the use of prostatilen and testilin for treating male infertility].
Boiko MI (1995) — Lik Sprava — PMID: 8630775
Using an experimental infertility model in male rats, prostatilen and testilin stimulated spermatogenesis and androgenic testicular function while helping normalize the androgen-estrogen balance, supporting possible clinical use in male infertility and hypoandrogenization.
strong
[The use of prostatilen in treating patients with chronic prostatitis].
Tkachuk VN et al. (1991) — Urol Nefrol (Mosk) — PMID: 1823682
Russian clinical trial in 307 chronic prostatitis patients reported symptom improvement after 5-10 mg IM daily for 5-10 days, with benefit in pain, urinary symptoms, sexual function, and general condition; evidence is older and language-limited, so it should be treated cautiously.
emerging
[The treatment with the polypeptide preparation "Prostatilen" of patients with prostatitis complicated by a sexual functional disorder]
Gorpinchenko II et al. (1991) — Vrach Delo — PMID: 2058122
Russian comparative clinical report described anti-inflammatory, antibacterial, and immunomodulating effects with improved urination and sexual/reproductive function in prostatitis patients; evidence is historical and limited, so it should remain caveated.
emerging

Build a personalized protocol with Prostatilen →